Since both IgA and IFN-γ are associated with amebiasis immunity in humans, we sought to develop an adjuvant formulation amenable to parenteral and mucosal delivery with the potential to enhance both mucosal antibody as well as Th1 cell responses. Here, CD79A is linked to amebiasis.